The role of DNA hypermethylation and demethylation in cancer and cancer therapy

Current Oncology

Volumn 15, Issue 2, 2008, Pages 2-5

  Szyf, Moshe ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AZACITIDINE; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE INHIBITOR; MG 98; S ADENOSYLMETHIONINE; SMALL INTERFERING RNA; ZEBULARINE;

CANCER INHIBITION; CANCER INVASION; CANCER THERAPY; CLINICAL TRIAL; DNA METHYLATION; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CANCER; METASTASIS INHIBITION; MYELODYSPLASTIC SYNDROME; SOLID TUMOR; TUMOR GENE; UNSPECIFIED SIDE EFFECT;

EID: 53349163022     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v15i2.210     Document Type: Editorial

References (32)

1. Rountree MR, Bachman KE, Hermann Baytin SB. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001;20:3156-65.
2. Razin A, Szyf M. DNA methylation patterns. Formation and function. Biochim Biophys Acta 1984;782:331-42.
3. Razin A. CpG methylation, chromatin structure and gene silencing - a three-way connection. EMBO J 1998; 17:4905-8.
4. Szyf M. DNA methylation properties: consequences for pharmacology. Trends Pharmacol Sci l994;115:233-8
5. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
6. Issa JP, Vertino PM, WU et al. increased cytosine DNA-methyltrasferase activity during colon cancer progression. J Natl Cancer Inst 1993;85:1235-40.
7. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13.
8. Novik KL, Nimmrich I, Genc B, et al. Epigenomics: genomewide study of methylation phenomena. Curr Issues Mol Biol 2002;4:111-28.
9. Szyf M, Bozovic V, Tanigawa G. Growth regulation of mouse DNA methyltransferase gene expression. J Biol Chem 1991;266:10027-30.
10. Torrisani J, Unterberger A, Tendulkar SR, Shikimi K, Szyf M. AUF1 cell cycle variations define genomic DNA methylation by regulation of DNMT1 MRNA stability. Mol Cell Biol 2007;27:395-410.
11. MacLeod AR, Rouleau J, Szyf M. Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem 1995;270:11327-37.
12. Detich N, Ramchandani S, SzyfM. A conserved 3′-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity. J Biol Chem 2001;276:24881-90.
13. MacLeod AR, Szyf M. Expression of antisense to DNA methyltransferase MRNA induces DNA demethylation and inhibits tumorigenesis. J Biol Chem 1995;270:8037-43.
14. Ramchandani S, MacLeod AR, Pinard M, von Hofe E, Szyf M. Inhibition of tumorigenesis by a cytosine-DNA, methyttransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1997;94:684-9.
15. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
16. Milutinovic S, Knox JD, Szyf M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdil). J Biol Chem 2000;275:6353-9.
17. Unterberger A, Andrews SD, Weaver IC, Szyf M. DNA methyltransferase 1 knockdown activates a replication stress checkpoint. Mol Cell Biol 2006;26:7575-86.
18. Szyf M. Targeting DNA methylation in cancer. Ageing Res Rev 2003;2:299-328.
19. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
20. Oki Y, Aoki E, Issa JP. Decitabine - bedside to bench. Crit Rev Oncol Hematol 2007;61:140-52.
21. Weiss AJ, Metter GE, Nealon TF, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep 1977;61:55-8.
22. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-8.
23. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95:399-409.
24. Davis AJ, Gelmon KA, Siu LL, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003;21:85-97.
25. Knox JD, Araujo FD, Bigey P, et al. Inhibition Of DNA methyltransferase inhibits DNA replication. J Biol Chem 2000;275:17986-90.
26. Szyf M, Pakneshan P, Rabbani SA. DNA demethylation and cancer: therapeutic implications. Cancer Lett 2004;211:133-43.
27. Shteper PJ, Zcharia E, Ashhab Y, Peretz T, Vlodavsky I, BenYehuda D. Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 2003;22:7737-49.
28. Pakneshan P, Szyf M, Farias-Eisner F, Rabbani SA. Reversal of the hypomethylation status of urokinase (UPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 2004;279:31735-44.
29. Detich N, Hamm S, Just G, Knox JD, Szyf M. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem 2003;278:20812-20.
30. Pascale RM, Simile MM, Satta G, et al. Comparative effects of L-methionine, S-adenosyl-L-methionine and 5′-methylthioadenosine on the growth of preneoplastic lesions and DNA methylation in rat liver during the early stages of hepatocarcinogenesis. Anticancer Res 1991;11:1617-24.
31. Shukeir N, Pakneshan P, Chen G, Szyf M, Rabbani SA. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res 2006;66:9202-10.
32. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA [see comments]. Nature 1999;397:579-83.